Literature DB >> 23708069

Chemoradiation for definitive, preoperative, or postoperative therapy of locally advanced non-small cell lung cancer.

Josephine Feliciano1, Steven Feigenberg, Minesh Mehta.   

Abstract

Over the last few decades, the integration of chemotherapy and radiation has played a crucial role in the management of locally advanced non-small cell lung cancer (NSCLC). Locally advanced NSCLC is a very heterogeneous disease. Because of this heterogeneity, advanced NSCLC can be managed in various ways depending on the bulk of disease, the comorbidities of the patient, and the expertise and resources of the treating physicians and facilities. This review describes the evolution of current treatment strategies and predicted future changes for the management of locally advanced NSCLC.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23708069      PMCID： PMC3703658          DOI： 10.1097/PPO.0b013e318293238d

Source DB:  PubMed          Journal:  Cancer J        ISSN： 1528-9117            Impact factor:   3.360


  78 in total

1.  Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva).

Authors:  Prakash Chinnaiyan; Shyhmin Huang; Geetha Vallabhaneni; Eric Armstrong; Sooryanarayana Varambally; Scott A Tomlins; Arul M Chinnaiyan; Paul M Harari
Journal:  Cancer Res       Date:  2005-04-15       Impact factor: 12.701

2.  A controlled study of postoperative radiotherapy for patients with completely resected nonsmall cell lung carcinoma. Groupe d'Etude et de Traitement des Cancers Bronchiques.

Authors:  B Dautzenberg; R Arriagada; A B Chammard; A Jarema; M Mezzetti; K Mattson; J L Lagrange; C Le Pechoux; B Lebeau; C Chastang
Journal:  Cancer       Date:  1999-07-15       Impact factor: 6.860

3.  Potential impact on survival of improved tumor downstaging and resection rate by preoperative twice-daily radiation and concurrent chemotherapy in stage IIIA non-small-cell lung cancer.

Authors:  N C Choi; R W Carey; W Daly; D Mathisen; J Wain; C Wright; T Lynch; M Grossbard; H Grillo
Journal:  J Clin Oncol       Date:  1997-02       Impact factor: 44.544

4.  Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B.

Authors:  Everett E Vokes; James E Herndon; Michael J Kelley; M Giulia Cicchetti; Nithya Ramnath; Harvey Neill; James N Atkins; Dorothy M Watson; Wallace Akerley; Mark R Green
Journal:  J Clin Oncol       Date:  2007-04-02       Impact factor: 44.544

5.  Phase II study of cetuximab in combination with chemoradiation in patients with stage IIIA/B non-small-cell lung cancer: RTOG 0324.

Authors:  George R Blumenschein; Rebecca Paulus; Walter J Curran; Francisco Robert; Frank Fossella; Maria Werner-Wasik; Roy S Herbst; Philip O Doescher; Hak Choy; Ritsuko Komaki
Journal:  J Clin Oncol       Date:  2011-05-09       Impact factor: 44.544

6.  Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.

Authors:  K Furuse; M Fukuoka; M Kawahara; H Nishikawa; Y Takada; S Kudoh; N Katagami; Y Ariyoshi
Journal:  J Clin Oncol       Date:  1999-09       Impact factor: 44.544

Review 7.  ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer.

Authors:  David Raben; Barbara A Helfrich; Dan Chan; Gary Johnson; Paul A Bunn
Journal:  Semin Oncol       Date:  2002-02       Impact factor: 4.929

8.  The interaction of epidermal growth factor and radiation in human head and neck squamous cell carcinoma cell lines with vastly different radiosensitivities.

Authors:  J A Bonner; N J Maihle; B R Folven; T J Christianson; K Spain
Journal:  Int J Radiat Oncol Biol Phys       Date:  1994-05-15       Impact factor: 7.038

9.  Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.

Authors:  Jean-Pierre Pignon; Hélène Tribodet; Giorgio V Scagliotti; Jean-Yves Douillard; Frances A Shepherd; Richard J Stephens; Ariane Dunant; Valter Torri; Rafael Rosell; Lesley Seymour; Stephen G Spiro; Estelle Rolland; Roldano Fossati; Delphine Aubert; Keyue Ding; David Waller; Thierry Le Chevalier
Journal:  J Clin Oncol       Date:  2008-05-27       Impact factor: 44.544

10.  A randomized study of involved-field irradiation versus elective nodal irradiation in combination with concurrent chemotherapy for inoperable stage III nonsmall cell lung cancer.

Authors:  Shuanghu Yuan; Xindong Sun; Minghuan Li; Jinming Yu; Ruimei Ren; Yonghu Yu; Jianbin Li; Xiuqing Liu; Renben Wang; Baosheng Li; Li Kong; Yong Yin
Journal:  Am J Clin Oncol       Date:  2007-06       Impact factor: 2.339
View more
  6 in total

1.  Prospective Study of Patient-Reported Symptom Burden in Patients With Non-Small-Cell Lung Cancer Undergoing Proton or Photon Chemoradiation Therapy.

Authors:  Xin Shelley Wang; Qiuling Shi; Loretta A Williams; Ritsuko Komaki; Daniel R Gomez; Steven H Lin; Joe Y Chang; Michael S O'Reilly; Raza H Bokhari; James D Cox; Radhe Mohan; Charles S Cleeland; Zhongxing Liao
Journal:  J Pain Symptom Manage       Date:  2016-02-16       Impact factor: 3.612

2.  High expression of Rad51c predicts poor prognostic outcome and induces cell resistance to cisplatin and radiation in non-small cell lung cancer.

Authors:  Xiuli Chen; Dong Qian; Jingjing Cheng; Yong Guan; Bin Zhang; Xiaofeng Ding; Jing Zeng; Xi Chen; Puchun Er; Furong Zhang; Na Zhao; Xiaocen Chen; Lujun Zhao; Zhiyong Yuan; Qingsong Pang; Ping Wang
Journal:  Tumour Biol       Date:  2016-07-27

3.  Minocycline Reduces Chemoradiation-Related Symptom Burden in Patients with Non-Small Cell Lung Cancer: A Phase 2 Randomized Trial.

Authors:  Xin Shelley Wang; Qiuling Shi; Tito Mendoza; Steven Lin; Joe Y Chang; Raza H Bokhari; Hui-Kai Lin; Araceli Garcia-Gonzalez; Mona Kamal; Charles S Cleeland; Zhongxing Liao
Journal:  Int J Radiat Oncol Biol Phys       Date:  2019-10-15       Impact factor: 7.038

4.  Postoperative radiation therapy following the incomplete resection of a non-small cell lung cancer.

Authors:  Jaehyeon Park; Si Yeol Song; Su Ssan Kim; Sang-We Kim; Woo Sung Kim; Seung-Il Park; Dong Kwan Kim; Yong-Hee Kim; Jongmoo Park; Sang-Wook Lee; Jong Hoon Kim; Seung Do Ahn; Eun Kyung Choi
Journal:  Radiat Oncol J       Date:  2014-06-30

5.  Synthetic Secoisolariciresinol Diglucoside (LGM2605) Protects Human Lung in an Ex Vivo Model of Proton Radiation Damage.

Authors:  Anastasia Velalopoulou; Shampa Chatterjee; Ralph A Pietrofesa; Cynthia Koziol-White; Reynold A Panettieri; Liyong Lin; Stephen Tuttle; Abigail Berman; Constantinos Koumenis; Melpo Christofidou-Solomidou
Journal:  Int J Mol Sci       Date:  2017-11-25       Impact factor: 5.923

6.  Somatic mutations combined with clinical features can predict the postoperative prognosis of stage IIIA lung adenocarcinoma.

Authors:  Jiuzhen Li; Xuefeng Lin; Xin Li; Weiran Zhang; Daqiang Sun
Journal:  Ann Transl Med       Date:  2022-02
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.